Déjà Vu All over Again: a Recurrent Flaw in Anticoagulant Study Design

Overview

Journal J Thromb Haemost

Publisher Elsevier

Specialty Hematology

Date 2024 Oct 30

PMID 39476970

Authors

Bethany Samuelson Bannow

Alison Edelman

Marc Carrier

Affiliations

Soon will be listed here.

Abstract

The availability of direct oral anticoagulants rapidly changed the landscape of anticoagulation between 2010 and the present. Randomized controlled trials demonstrating efficacy with similar or superior safety compared with warfarin led to the widespread use of direct oral anticoagulants in male and female patients of all ages. Years later, postmarketing data demonstrated a markedly increased rate of heavy menstrual bleeding (HMB) with rivaroxaban that had gone undetected in registry trials. Factor (F)XI inhibitors are currently being investigated as another alternative to available anticoagulation agents. While generally mild, the phenotype of inherited FXI deficiency includes bleeding in tissues with enhanced fibrinolysis, including HMB. Thus, we aimed to perform a systematic review of published studies on FXI inhibitors in order to estimate rates of HMB. However, we found that few studies included menstruating individuals, and even fewer specifically reported on uterine bleeding, highlighting once again a flaw in our approach to conducting trials of new anticoagulants.

References

Verhamme P, Yi B, Segers A, Salter J, Bloomfield D, Buller H . Abelacimab for Prevention of Venous Thromboembolism. N Engl J Med. 2021; 385(7):609-617. DOI: 10.1056/NEJMoa2105872. View

Xia Y, Hu Y, Tang L . Factor XIa Inhibitors as a Novel Anticoagulation Target: Recent Clinical Research Advances. Pharmaceuticals (Basel). 2023; 16(6). PMC: 10300994. DOI: 10.3390/ph16060866. View

Weitz J, Strony J, Ageno W, Gailani D, Hylek E, Lassen M . Milvexian for the Prevention of Venous Thromboembolism. N Engl J Med. 2021; 385(23):2161-2172. PMC: 9540352. DOI: 10.1056/NEJMoa2113194. View

Bryk A, Pirog M, Plens K, Undas A . Heavy menstrual bleeding in women treated with rivaroxaban and vitamin K antagonists and the risk of recurrent venous thromboembolism. Vascul Pharmacol. 2016; 87:242-247. DOI: 10.1016/j.vph.2016.11.003. View

Hamulyak E, Wiegers H, Hutten B, de Lange M, Timmermans A, Westerweel P . Heavy menstrual bleeding on direct factor Xa inhibitors: the MEDEA randomized clinical trial. Res Pract Thromb Haemost. 2024; 8(4):102448. PMC: 11215107. DOI: 10.1016/j.rpth.2024.102448. View

Samuelson Bannow B, Chi V, Sochacki P, McCarty O, Baldwin M, Edelman A . Heavy menstrual bleeding in women on oral anticoagulants. Thromb Res. 2020; 197:114-119. PMC: 7775335. DOI: 10.1016/j.thromres.2020.11.014. View

Huisman M, Ferreira M, Feuring M, Fraessdorf M, Klok F . Less abnormal uterine bleeding with dabigatran than warfarin in women treated for acute venous thromboembolism. J Thromb Haemost. 2018; 16(9):1775-1778. DOI: 10.1111/jth.14226. View

Weitz J, Bauersachs R, Becker B, Berkowitz S, Freitas M, Lassen M . Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial. JAMA. 2020; 323(2):130-139. PMC: 6990695. DOI: 10.1001/jama.2019.20687. View

Piccini J, Caso V, Connolly S, Fox K, Oldgren J, Jones W . Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet. 2022; 399(10333):1383-1390. DOI: 10.1016/S0140-6736(22)00456-1. View

10.

Matteson K, Scott D, Raker C, Clark M . The menstrual bleeding questionnaire: development and validation of a comprehensive patient-reported outcome instrument for heavy menstrual bleeding. BJOG. 2015; 122(5):681-9. PMC: 4373964. DOI: 10.1111/1471-0528.13273. View

11.

Godin R, Marcoux V, Tagalakis V . Abnormal uterine bleeding in women receiving direct oral anticoagulants for the treatment of venous thromboembolism. Vascul Pharmacol. 2017; 93-95:1-5. DOI: 10.1016/j.vph.2017.05.001. View

12.

Warner P, Critchley H, Lumsden M, Campbell-Brown M, Douglas A, Murray G . Menorrhagia I: measured blood loss, clinical features, and outcome in women with heavy periods: a survey with follow-up data. Am J Obstet Gynecol. 2004; 190(5):1216-23. DOI: 10.1016/j.ajog.2003.11.015. View

13.

Kaatz S, Ahmad D, Spyropoulos A, Schulman S . Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2016; 13(11):2119-26. DOI: 10.1111/jth.13140. View

14.

De Crem N, Peerlinck K, Vanassche T, Vanheule K, Debaveye B, Middeldorp S . Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists. Thromb Res. 2015; 136(4):749-53. DOI: 10.1016/j.thromres.2015.07.030. View

15.

Buller H, Bethune C, Bhanot S, Gailani D, Monia B, Raskob G . Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2014; 372(3):232-40. PMC: 4367537. DOI: 10.1056/NEJMoa1405760. View